Evidence map›Paper›PMID 34677664›Full record

ArticleEuropean journal of pediatrics2022

SARS-CoV-2 seroprevalence in children and their family members, July-October 2020, Brussels.

Lorraine Dethioux, Nicolas Dauby, Isabel Montesinos, Elisabeth Rebuffat, Marc Hainaut

Open access · bronzeAbstract read
In one paragraph

Article in European journal of pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Lorraine DethiouxPediatrics Department, CHU Saint-Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium. lorraine.dethioux@ulb.be.ORCID http://orcid.org/0000-0003-2425-9693
Nicolas DaubyInfectious Diseases Department, CHU Saint-Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium.ORCID http://orcid.org/0000-0002-7697-6849
Isabel MontesinosMicrobiology Department, Laboratoire Hospitalier Universitaire de Bruxelles (LHUB-ULB), Brussels, Belgium.ORCID http://orcid.org/0000-0002-1956-5330
Elisabeth RebuffatPediatrics Department, CHU Saint-Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium.ORCID http://orcid.org/0000-0003-4672-9238
Marc HainautPediatrics Department, CHU Saint-Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium.ORCID http://orcid.org/0000-0002-6421-3078
Université Libre de Bruxelles · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to estimate the seroprevalence of SARS-CoV-2 antibodies in a pediatric population after the first pandemic wave in Belgium. All patients requiring a blood sample between 1 July 2020 and 31 October 2020 in our institution were invited to participate. Their parents and siblings could also participate to estimate familial transmission and the congruence between serological statuses. A questionnaire was completed for each participant to identify symptoms consistent with COVID-19 in the previous months. Blood samples were tested for SARS-CoV-2-specific immunoglobulin G using ELISA. The final population included 112 children, 24 siblings of these children, and 36 adults. The seroprevalence of cases was 6.9% before 8 September, a date that corresponds to 1 week after the beginning of the second wave in Belgium and 22.5% afterwards (OR = 3.89, 95% CI (1.20; 12.58), p-value = 0.03). Twenty-five percent of children were asymptomatic, and none experienced severe disease. The symptoms associated with SARS-CoV-2-positive antibodies were diarrhoea (OR = 9.9, 95% CI [2.88; 33.87.65] p-value < 0.01), fever (OR = 3.8, 95% CI [1.44; 10.22] p-value < 0.01), rhinitis (OR = 3.9, 95% CI [1.38; 10.90] p-value = 0.01), or anosmia (OR = 31.5, 95% CI [1.45; 682.7], p-value = 0.02). A child was the first symptomatic household member in 50% of the familial clusters.Conclusion: Seroprevalence in children was comparable to that of the general population. Children could represent the source of infection in the household. What is Known: • COVID-19 infection is generally mild or asymptomatic in children and adolescents. • Belgian strategy of testing was focused on symptoms. • Adults are believed to be responsible for most of familial clusters. What is New: • Serological testing gives a more accurate view of the rate of infected children. • Based on serological results, children have been infected as frequently as adults during the first and second wave in Belgium. • Seventy-five percent of SARS-CoV-2 IgG-positive children presented a mild symptomatology, and 25% were totally asymptomatic. • Children could represent the source of infection within household.

Indexed as

COVID-19SARS-CoV-2AdolescentAdultAntibodies, ViralChildFamilyHumansPandemicsSeroepidemiologic StudiesAntibodies, ViralChildrenFamilial transmissionSARS-CoV-2 antibodiesSeroprevalence

Identifiers

PMID34677664
PMCPMC8532097
OpenAlexW3205445809

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.